A Phase 1 Study of BHV-1530 in Advanced Solid Tumors

Official title

A Phase 1, Multicenter, Open-Label, Dose Escalation, Dose Expansion and Dose Optimization Study of BHV-1530 as Monotherapy and in Combination With Other Anti-Cancer Agents in Adult Participants With Advanced or Metastatic Solid Tumors

Overview

This is a Phase 1, first in human (FIH), Open-Label, Dose Escalation, Dose Expansion and Dose Optimization Study of BHV-1530 as Monotherapy and in Combination with Other Anti-Cancer Agents in Adult Participants with Advanced or Metastatic Solid Tumors

Interventions

• Drug BHV-1530
  BHV-1530 will be administered as an IV infusion on Day 1 of each 21-day cycle
• Drug Cemiplimab
  cemiplimab (350 mg) will be administered as an IV infusion on Day 1 of each 21-day cycle

Primary outcome measures

• Dose-escalation and Dose-expansion Cohorts: To determine the safety profile, maximum tolerable dose (MTD), minimally reproducible active dose (MRAD), and recommended dose range (RDR) of BHV-1530 monotherapy and BHV-1530 in combination with cemiplimab [Time frame: Through study completion, estimated as an average of 48 months]
• Dose-optimization Cohorts: Recommended dose of BHV-1530 for later phase trials [Time frame: Through study completion, estimated as an average of 48 months]

Secondary outcome measures (12)

• Dose-escalation and Dose-expansion Cohorts: Clinical Benefit Rate (CBR) [Time frame: Through study completion, estimated as an average of 48 months]
• Dose-escalation and Dose-expansion Cohorts: Objective Response Rate (ORR) [Time frame: Through study completion, estimated as an average of 48 months]
• Dose-escalation and Dose-expansion Cohorts: Disease Control Rate (DCR) [Time frame: Through study completion, estimated as an average of 48 months]
• Dose-escalation and Dose-expansion Cohorts: Time to Response (TTR) [Time frame: Through study completion, estimated as an average of 48 months]
• Dose-escalation and Dose-expansion Cohorts: Duration of Response (DOR) [Time frame: Through study completion, estimated as an average of 48 months]
• Dose-escalation and Dose-expansion Cohorts: Progression-free Survival (PFS) [Time frame: Through study completion, estimated as an average of 48 months]
• Dose-escalation and Dose-expansion Cohorts: Maximum observed serum concentration (Cmax) [Time frame: Through study completion, estimated as an average of 48 months]
• Dose-escalation and Dose-expansion Cohorts: Time of maximum concentration (Tmax) [Time frame: Through study completion, estimated as an average of 48 months]
• Dose-escalation and Dose-expansion Cohorts: Elimination half-life (t½) [Time frame: Through study completion, estimated as an average of 48 months]
• Dose-escalation and Dose-expansion Cohorts: Area Under the Concentration versus time curve (AUC) [Time frame: Through study completion, estimated as an average of 48 months]
• Dose-escalation and Dose-expansion Cohorts: Trough concentration (Ctrough) [Time frame: Through study completion, estimated as an average of 48 months]
• Dose-escalation and Dose-expansion Cohorts: Total body clearance (CL) [Time frame: Through study completion, estimated as an average of 48 months]

Eligibility criteria

Inclusion criteria

• Signed, written Independent Ethics Committee (IEC)/Institutional Review Board (IRB)-approved informed consent
• Age greater than or equal to 18 years
• Participants consent to provide tumor tissue collected prior to study treatment, preferably from a biopsy performed after their last anticancer therapy and within 90 days of the start of study treatment. An older archival sample may be acceptable with Sponsor approval.
• Participants must have progressed following, are intolerant of, or have no available standard-of-care therapy.
• Patients with histologically or cytologically confirmed locally advanced/metastatic relapsed or refractory solid tumors as outlined below:

• Dose Escalation and Dose Expansion (Backfill) Cohorts (BHV-1530 monotherapy):

• Participants with urothelial cancer of the urinary tract: (including renal pelvis, ureters, urinary bladder, and urethra), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) of the oral cavity, hypopharynx, oropharynx, nasopharynx, larynx and sinonasal tract.

• Tumors originating from the salivary glands, or unknown primary sites are not eligible.
• Other advanced or metastatic solid tumors with a documented activating FGFR3 alteration (mutation or fusion).
• Dose Escalation and Dose Expansion (Backfill) Cohorts (BHV-1530 in combination with cemiplimab):

• Participants with urothelial cancer of the urinary tract: (including renal pelvis, ureters, urinary bladder, and urethra), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) of the oral cavity, hypopharynx, oropharynx, nasopharynx, larynx and sinonasal tract.

• Tumors originating from the salivary glands, or unknown primary sites are not eligible.
• Other advanced or metastatic solid tumors with a documented activating FGFR3 alteration (mutation or fusion).

Participants must have received ≤ 2 prior lines of systemic anti-cancer therapy which may include at most one prior anti-programmed cell death protein 1 (PD-1) (programmed death-ligand 1 \[PD-L1\]) therapy for advanced/metastatic disease.

Dose Optimization Cohorts (BHV-1530 monotherapy):

oParticipants with urothelial cancer of the urinary tract: (including renal pelvis, ureters, urinary bladder, and urethra)..

• Measurable advanced or metastatic tumors per RECIST 1.1 criteria
• Patients must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Acceptable liver function:

• Bilirubin ≤ 1.5 × upper limit of normal (ULN). Participants with known Gilbert's syndrome who have total bilirubin level ≤3×ULN may be enrolled.
• AST, ALT, and alkaline phosphatase ≤ 2.5 × ULN (if liver metastases are present, then ≤ 5 × ULN is allowed)
• Acceptable renal function:

• Serum creatinine ≤1.5 × ULN, or creatinine clearance ≥50 mL/min as calculated using the modified Cockcroft-Gault equation; confirmation of creatinine clearance is only required when creatinine is >1.5 × ULN; 24-hour urine collection is allowed, but not required
• Acceptable hematologic status:

• Blood transfusion or growth factor support is not allowed within 7 days prior to blood samples that will be used to establish eligibility
• Absolute neutrophil count greater than or equal to 1500/mm3. Participants with known Duffy null phenotype who have absolute neutrophil count ≥ 1,200/mm3 may be enrolled
• Platelet count greater than or equal to 100,000 mm3
• Hemoglobin greater than or equal to 9 g/dL
• Activated partial thromboplastin time (aPTT) ≤1.5×ULN. Study participants on therapeutic doses of anticoagulation medication must have INR and/or aPTT ≤ the upper limit of the therapeutic range for intended use
• A negative urine or serum pregnancy test (if a woman of childbearing potential);
• Women of childbearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation and for 7 months (for women) or 4 months (for men) after the last dose of study drug.

General Exclusion Criteria:

• Prior treatment with antibody drug conjugate (ADC) with a topoisomerase-I inhibitor payload. Prior direct treatment with topoisomerase inhibitor (e.g., irinotecan, topotecan, belotecan, nano-liposomal irinotecan) are not exclusionary.
• Participant has clinically significant intercurrent disease including, but not limited to:

• New York Heart Association Class III or IV heart failure
• Myocardial infarction, unstable angina, or stroke ≤ 6 months prior to C1D1
• Newly diagnosed thromboembolic events that require therapeutic intervention over the last 4 months prior to C1D1 (participants with stable control of lower limb deep venous thrombosis over at least 1 months are allowed, and participants with incidental, asymptomatic pulmonary embolism and clinically stable for at least 1 month prior to C1D1 are allowed)
• Severe aortic stenosis
• Uncontrolled arrhythmia
• Symptomatic pericardial effusion
• Congenital long QT syndrome
• A mean of Fredericia's formula-QT corrected interval (QTcF) prolongation to >470 msec based on a triplicate 12-lead ECG
• Uncontrolled hypertension (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg) or diabetes (hemoglobin A1C ≥9.0%)
• Left ventricular ejection fraction (LVEF) <45% determined by echocardiogram or multiple gated acquisition scan (MUGA)
• Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
• Primary central nervous system (CNS) tumors, current or previously treated leptomeningeal disease or known active brain metastases.

NOTE: Participants with previously treated, clinically stable, radiologically stable brain metastases maybe eligible

• Pregnant or nursing women
• Any standard cancer therapy (e.g., chemotherapy, hormonal therapy, radiotherapy, immunotherapy, biologic therapy treatment) or experimental therapy within 4 weeks or 5 half-lives, whichever is shorter, prior to C1D1. The interval may be reduced to 2 weeks for bone-only radiation therapy. Any major surgical procedure within 6 weeks prior to C1D1
• Participants have not recovered (i.e., improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo. If the participant has an ongoing, stable, chronic Grade 2 toxicity they may be eligible after discussion with Sponsor on a case-by-case basis
• Any clinically significant corneal or retinal abnormality that may increase the risk of eye toxicity
• Known active infection with human immunodeficiency virus (HIV), human T-cell leukemia virus, type 1 (HTLV-1), hepatitis B virus (HBV), or hepatitis C virus (HCV), if allowed by local regulations:

• Participants with hepatitis B (hepatitis B virus surface antigen \[HbsAg\] positive), or hepatitis C (hepatitis C virus \[HCV\] antibody positive, confirmed by HCV ribonucleic acid). Participants with HCV with undetectable virus after treatment are eligible. Participants with a prior history of hepatitis B virus are eligible if quantitative polymerase change reaction for hepatitis B virus DNA is negative
• Participants with human immunodeficiency virus (HIV) infection with acquired immune deficiency syndrome (AIDS) defining illness are not eligible for enrollment; however, participants who have had HIV infection and who have a cluster of differentiation 4 (CD4) + T cell count >350 cells/μL and no history of an AIDS-defining illness are eligible for entry
• Has an active second malignancy. Note: participants with a history of malignancy that have been completely treated, with no evidence of active cancer for 3 years prior to enrollment, or participants with tumors cured with radiotherapy or surgery with low risk of recurrence (e.g., non melanoma skin cancer, histologically confirmed complete excision of carcinoma in situ) are allowed
• Participants who in the opinion of the Investigator will not be able to adhere to the schedule of assessments and/or may have difficulties complying with the treatment regimen or are unwilling or unable to comply with procedures required in this protocol
• Known sensitivity to BHV-1530 or any of the excipients in BHV-1530;
• History of (noninfectious) clinically significant interstitial lung disease (ILD)/pneumonitis that required steroids, active clinically significant ILD/pneumonitis, or suspected clinically significant ILD/pneumonitis that cannot be ruled out by imaging at screening.
• Requires supplemental oxygen for daily activities
• Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment
• Combination Specific Exclusion Criteria:

To be eligible to participate in the combination arms of the study, participants must not meet the combination specific exclusion criteria in addition to the general exclusion criteria.

Hypersensitivity to cemiplimab or any of its excipients or contraindicated to cemiplimab per approved local labeling.

Experienced Grade 3 or higher immune-related AEs with prior treatment of anti-PD-1, anti PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137).

Prior allogeneic stem cell or solid organ transplantation.

Patients with history of myocarditis.

Presence of cardiovascular disease, as defined by:

New York Heart Association heart failure classifications of Class II, III, or IV; or myocardial infarction, or acute coronary syndrome within 12 months of first dose of study medication; or

Transient ischemic attack or stroke within 1 year.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Non-randomized

Model

Sequential

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 17 centers

• Site-111 — Newport Beach
• Site-107 — Denver
• Site-108 — Lake Mary
• Site-121 — Miami
• Site-118 — Orlando
• Site-120 — Ann Arbor
• Site-110 — Detroit
• Site-115 — Durham
• … and 9 more centers

Identifiers

NCT: NCT06874335 · BHV1530-101

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗